---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Diagnosis"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Diagnosis. Topics: Diagnostic criteria for major depression, Diagnostic assessment: structured interview and treatment history instruments, Confirming treatment resistance: retrospective assessment and screening for bipolarity, Confirming treatment resistance: excluding pseudo-resistance, and 8 further topics. 12 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/diagnosis"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Diagnostic criteria for major depression

> “The detection of MDD requires the presence of depressed mood or loss of interest and pleasure in activities accompanied by at least two (ICD-10) or five (DSM-5) symptoms of depression. These core symptoms may vary from patient to patient, however, they are typically seen for much of the day, almost always every day for at least two weeks and are associated with relevant psychological distress and considerable impairment in social, occupational, or other important areas of functioning.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-2.2.1.5-2"></a>

### Diagnostic assessment: structured interview and treatment history instruments

> “At a minimum, assessment to define TRD should include a structured clinical interview for the diagnosis of MDD, such as the Structured Clinical Interview for DSM (SCID) [53, 54] and the Mini-International Neuropsychiatric Interview (MINI) [55], together with a scale to assess the patient’s antidepressant history, such as the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ) [56], and the Antidepressant Treatment History Form (ATHF) [57]. A more structured method is to use staging models [6, 58], such as the Thase and Rush method [59], the Massachusetts General Hospital Staging model (MGH-s) [22], and the more recent Maudsley Staging Model (MSM) [60], which also allows the assessment of previous antidepressant treatment failure, using the Maudsley Treatment Inventory (MTI) [10].”
> “Among the experts, there was a substantial agreement that staging models are the preferred instrument to define TRD/PRD and assess the level of treatment-resistance, even if many experts recognize the validity of the ATRQ, often accepted in regulatory clinical trials.”

Source: [Sforzini et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9095475/)

<a id="topic-2.2.1.5-3"></a>

### Confirming treatment resistance: retrospective assessment and screening for bipolarity

> “Retrospective assessment of treatment failure should be primarily based on medical records of previous treatment if such records can be obtained, and not on the patient’s recollection of symptom improvement, which may be biased.”
> “Patients should be carefully screened for previous episodes of mania, hypomania or sub-threshold bipolarity and this would increase the accuracy of population selection”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-2.2.1.5-4"></a>

### Confirming treatment resistance: excluding pseudo-resistance

> “Reviewed herein are the most common modifiable contributors to pseudo‐resistance, including inaccuracy of the MDD diagnosis, inadequacy of current and past treatment trials, inaccurate assessment of response, and individual differences in the metabolism of antidepressants”
> “Inaccuracy of the MDD diagnosis is a common reason for pseudo‐resistance. It is estimated that approximately half of individuals with MDD are not correctly diagnosed”
> “Furthermore, it is reported that the transition from a diagnosis of MDD to one of bipolar disorder occurs at a rate of approximately 1‐3% per year, indicating that diagnostic assessment must be reconsidered in all TRD presentations”
> “The adequate duration of an antidepressant trial is generally considered to be 4‐6 weeks at optimal dosing, although 60% of persons who achieved remission in the STAR*D trial with level 1 treatment did so after week 6 of treatment, indicating that a subpopulation of adults with MDD may require longer treatment trials”
> “Using this definition, about 30‐50% of persons prescribed with antidepressants are non‐adherent in acute phase treatment”
> “Although pharmacogenetic testing cannot be recommended as a routine assessment in TRD, some preliminary evidence does suggest that, in select circumstances, it may be warranted.”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

> “Furthermore, determining the adequacy of prior treatment is essential since substantial evidence indicates that large numbers of depressed patients are undertreated, resulting in prolonged episodes and the appearance of "pseudoresistance."”

Source: [Sackeim (2001)](https://pubmed.ncbi.nlm.nih.gov/11480879/)

<a id="topic-2.2.1.5-5"></a>

### Guideline recommendation: reassessment after poor response

> “The first steps in the assessment of poor response involve re-evaluating the diagnosis (e.g., a missed diagnosis of bipolar disorder), comorbidities, and adherence to treatment. In addition to clinical reassessment, laboratory investigations should be considered to rule out potential medical factors that can contribute to persistent symptoms and that require additional interventions.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

> “A diagnostic re-evaluation is essential to the proper management of these patients. In particular, the potential role of several contributing factors, such as medical and psychiatric comorbidity, needs to be taken into account.”

Source: [Fava (2003)](https://pubmed.ncbi.nlm.nih.gov/12706951/)

<a id="topic-2.2.1.5-6"></a>

### Staging models: Thase and Rush model

> “In this paper, alternate antidepressant strategies are reviewed within the context of a five-stage strategy, ranging from lesser to greater degrees of treatment resistance. The overall strategy recommended progresses from simpler (i.e., an alternate monotherapy) to more complex strategies (i.e., combination or augmentation regimens), with the nonselective monoamine oxidase inhibitors (+/- lithium salts) and electroconvulsive therapy typically reserved for treatment of Stages III and IV of resistance, respectively.”

Source: [Thase and Rush (1997)](https://pubmed.ncbi.nlm.nih.gov/9402916/)

> “Stage I is defined by failure of at least one adequate trial of one major class of antidepressants; stage II by failure of at least two adequate trials of at least two distinctly different classes of antidepressants; stage III by stage II resistance plus failure of an adequate trial of a tricyclic antidepressant (TCA); stage IV by stage III resistance plus failure of an adequate trial of a monoamine oxidase inhibitor (MAOI); and stage V by stage IV resistance plus failure of a course of bilateral electroconvulsive therapy (ECT).”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.5-7"></a>

### Staging models: Maudsley Staging Method

> “We present a points-based staging model incorporating 3 factors: treatment, severity of illness, and duration of presenting episode. In this model, the rating of symptom severity ranges from subsyndromal depression (score 1) to severe syndromal depression with psychosis (score 5). Antidepressant treatment is rated on a 5-point subscale based on number of medications used, while duration of the presenting episode is rated on a 3-point subscale. The overall level of resistance estimated using this model varies from minimal resistance (score of 3) to severe resistance (score of 15).”

Source: [Fekadu et al. (2009b)](https://pubmed.ncbi.nlm.nih.gov/19192471/)

> “The core dimension of the MSM, treatment failure, may be assessed using the Maudsley Treatment Inventory (MTI), a new method developed for the purposes of completing the MSM. The MTI consists of a relatively comprehensive list of medications with options for rating doses and provisions treatment for multiple episodes. The second dimension, severity of symptoms, may be assessed using simple instruments such as the Clinical Global Impression, the Psychiatric Status Rating or checklist from a standard diagnostic checklist. The standardisation also provides a simple rating scale for scoring the third dimension, duration of depressive episode.”

Source: [Fekadu et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5896127/)

<a id="topic-2.2.1.5-8"></a>

### Staging models: Massachusetts General Hospital model

> “One point is assigned for non‐response to each adequate trial of a marketed antidepressant (duration of at least six weeks and adequate dosage). Half a point is assigned for each trial based on optimization of dose, optimization of duration, or an augmentation/combination strategy. Three points are assigned for non‐ response to ECT.”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.5-9"></a>

### Staging models: systematic review of five models

> “From 950 retrieved articles five staging models were found; the Antidepressant Treatment History Form, Thase and Rush Model, European Staging Model, Massachusetts General Hospital Staging model and the Maudsley Staging Model (MSM). Six studies investigated the predictive utility (of four models). We observed an evolution from single antidepressant adequacy ratings, towards a multidimensional and more continuous scored staging model which also introduced TRD characteristics (severity and duration). The operationalization criteria improved; the scoring of different treatment strategies (between/within class switching and augmentation/combination) changed according to the existing evidence. Over time, efforts to validate models improved. The predictive utility was assessed best for the MSM.”
> “Few staging models existed; their reliability was hardly assessed.”

Source: [Ruhé et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/21435727/)

<a id="topic-2.2.1.5-10"></a>

### Rating scales: instruments accepted for trials

> “Acceptable scales to determine symptomatic improvement include the Hamilton Rating Scale of Depression (HDRS), preferably the 17-item scale, and the Montgomery-Asberg Depression Rating Scale (MADRS), however other validated scales might be acceptable as well.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

> “We recommend (with moderate consensus) that the clinician administered MADRS10 is the preferred outcome instrument to assess treatment response (and remission) (85%), together with patient-reported QIDS-SR (81%).”

Source: [Sforzini et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9095475/)

<a id="topic-2.2.1.5-11"></a>

### Rating scales: Montgomery-Åsberg Depression Rating Scale development

> “Ratings on these 17 items for 64 patients participating in studies of four different antidepressant drugs were used to create a depression scale consisting of the 10 items which showed the largest changes with treatment and the highest correlation to overall change.”
> “Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.”

Source: [Montgomery and Asberg (1979)](https://pubmed.ncbi.nlm.nih.gov/444788/)

<a id="topic-2.2.1.5-12"></a>

### Rating scales: response, nonresponse, and remission thresholds

> “Early improvement is often defined with a symptom scale as a reduction in score of 20% or greater from baseline (within 2 to 4 weeks after treatment initiation), whereas response is defined as 50% or greater improvement from baseline. Symptom remission is indicated by a specific threshold score for each scale, e.g., a score of 7 or less on the Hamilton Depression Rating Scale (HAM-D), 10 or less on the Montgomery-Åsberg Depression Rating Scale (MADRS), and 4 or less on the PHQ-9.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

> “An exception is the GSRD staging method 14 , which explicitly defines treatment non‐response as a reduction of less than 50% in the total score on the HAM‐D or the MADRS.”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

> “On the basis of a narrow definition of remission, which requires a complete absence of clinically significant symptoms of depression, the optimal MADRS cutoff was < or = 4. On the basis of a broader definition, the optimal cutoff was < or = 9.”

Source: [Zimmerman et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15003068/)

> “Our results confirm the validity of the commonly used measures for response in MDD trials: a CGI-I score of 2 ('much improved') corresponded to a percentage MADRS reduction from baseline of 48-57%, and a CGI-I score of 1 ('very much improved') to a reduction of 80-84%. If a state of almost complete absence of symptoms were required for a definition of remission, a MADRS total score would be <8, because such scores corresponded to a CGI-S score of 2 ('borderline mentally ill').”

Source: [Leucht et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28068617/)

Additional sources: [Hamilton (1960)](https://pmc.ncbi.nlm.nih.gov/articles/PMC495331/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
